A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live

Inclusion Criteria:

1. Signed and dated written informed consent in accordance with International Councilon Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior toadmission to the trial

2. Male or female who is ≥ 18 (or who is of legal age in countries where that isgreater than 18) and ≤ 75 years old at screening

3. Clinical signs of Clinically Significant Portal Hypertension (CSPH) as described byeither one of the points below. Each trial patient must have a gastroscopy duringthe screening period or within 6 months prior to screening.

• documented endoscopic proof of oesophageal varices and / or gastric varices atscreening or within 6 months prior to screening

• documented endoscopic-treated oesophageal varices as preventative treatment

4. CSPH defined as baseline Hepatic Venous Pressure Gradient (HVPG) ≥ 10 mmHg, based ona local interpretation of the pressure tracing

5. Diagnosis of compensated alcohol-related cirrhosis. Diagnosis must be based onhistology (historical data is acceptable) or on clinical evidence of cirrhosis (e.g.platelet count < 150 x 10^9/L [150 x 10^3/µL], nodular liver surface on imaging orsplenomegaly)

6. Abstinence from significant alcohol misuse / abuse for a minimum of 2 months priorto screening, and the ability to abstain from alcohol throughout the trial (bothevaluated based on Investigator judgement)

7. Willing and able to undergo HVPG measurements per protocol (based on Investigatorjudgement)

8. If receiving statins must be on a stable dose for at least 3 months prior toscreening, with no planned dose change throughout the trial Further inclusioncriteria apply.

Exclusion Criteria:

1. Previous clinically significant decompensation events (e.g. ascites [more thanperihepatic ascites], Variceal Haemorrhage (VH) and / or apparent HepaticEncephalopathy (HE))

2. History of other forms of chronic liver disease (e.g. non-alcoholic steatohepatitis (NASH), Hepatitis B virus (HBV), untreated Hepatitis C Virus (HCV), autoimmune liverdisease, primary biliary cholangitis, primary sclerosing cholangitis, Wilson'sdisease, haemachromatosis, alpha-1 antitrypsin (A1At) deficiency)

3. Has received curative anti-viral therapy with direct-acting anti-virals within thelast 2 years for HCV, or, if such treatment was > 2 years ago and there is nosustained virological response (SVR) at screening, or, must take curative anti-viraltherapy with direct-acting anti-virals throughout the trial

4. Alcohol-Related Liver Disease (ARLD) without adequate treatment (e.g. lifestylemodification) or with ongoing pathological drinking behaviour (misuse / abuse basedon Investigator judgement)

5. Must take, or wishes to continue the intake of, restricted concomitant therapy orany concomitant therapy considered likely (based on Investigator judgement) tointerfere with the safe conduct of the trial

6. Systolic Blood Pressure (SBP) < 100 mmHg and Diastolic Blood Pressure (DBP) < 70mmHg at screening

7. Model of End-stage Liver Disease (MELD) score of > 15 at screening, calculated bythe central laboratory

8. Hepatic impairment defined as a Child-Turcotte-Pugh score ≥ B8 at screening,calculated by the site, using central laboratory results Further exclusion criteriaapply.